Single Ascending Oral Dose Study to Investigate the Effects of OCT461201 in Healthy Volunteers

NCT06398925 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

32

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: OCT461201 50 mg
DRUG: OCT461201 100 mg
DRUG: OCT461201 150 mg
DRUG: OCT461201 450 mg
DRUG: Placebo

Sponsor

Oxford Cannabinoid Technologies Holdings PLC

Collaborators

[object Object]